Depression market value to drop as pharma battles second cliff
This article was originally published in Scrip
Executive Summary
As the second patent cliff for top-selling depression drugs approaches, the value of the depression market is set to decline from $5.6bn in 2012 to $4.7bn in 2016 in the seven major markets, new analysis indicates.